Lasofoxifene for postmenopausal women with osteoporosis.
Malozowski
Saul
S
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D057186:Comparative Effectiveness Research; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006381:Helsinki Declaration; D006801:Humans; D007258:Informed Consent; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010919:Placebos; D011759:Pyrrolidines; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene